A new series of potent oxindole inhibitors of CDK2
- PMID: 15012993
- DOI: 10.1016/j.bmcl.2003.12.009
A new series of potent oxindole inhibitors of CDK2
Abstract
A novel series of oxindole-type inhibitors of CDK2 that have heteroatom substituted alkynyl moieties at their C-4 position is described. These novel 4-alkynyl-substituted inhibitors have superior potency relative to their parent compound in free enzyme and in cell based assays. The crystal structure of CDK2 in complex with one of these analogues was determined and gives insight to their increased potency. The biochemical evaluation of a representative derivative is also described.
Similar articles
-
Synthesis of potent oxindole CDK2 inhibitors.Bioorg Med Chem. 2003 Apr 17;11(8):1873-81. doi: 10.1016/s0968-0896(03)00036-1. Bioorg Med Chem. 2003. PMID: 12659774
-
Discovery and in vitro evaluation of potent TrkA kinase inhibitors: oxindole and aza-oxindoles.Bioorg Med Chem Lett. 2004 Feb 23;14(4):953-7. doi: 10.1016/j.bmcl.2003.12.002. Bioorg Med Chem Lett. 2004. PMID: 15013000
-
Preparation of novel aza-1,7-annulated indoles and their conversion to potent indolocarbazole kinase inhibitors.Bioorg Med Chem Lett. 2004 Aug 2;14(15):3925-8. doi: 10.1016/j.bmcl.2004.05.088. Bioorg Med Chem Lett. 2004. PMID: 15225699
-
Benzodipyrazoles: a new class of potent CDK2 inhibitors.Bioorg Med Chem Lett. 2005 Mar 1;15(5):1315-9. doi: 10.1016/j.bmcl.2005.01.023. Bioorg Med Chem Lett. 2005. PMID: 15713378
-
An analysis of the binding modes of ATP-competitive CDK2 inhibitors as revealed by X-ray structures of protein-inhibitor complexes.Curr Med Chem Anticancer Agents. 2005 Sep;5(5):561-73. doi: 10.2174/1568011054866928. Curr Med Chem Anticancer Agents. 2005. PMID: 16178778 Review.
Cited by
-
Selectivity and potency of cyclin-dependent kinase inhibitors.AAPS J. 2006 Mar 24;8(1):E204-21. doi: 10.1208/aapsj080125. AAPS J. 2006. PMID: 16584130 Free PMC article. Review.
-
Identification of 3-(piperazinylmethyl)benzofuran derivatives as novel type II CDK2 inhibitors: design, synthesis, biological evaluation, and in silico insights.J Enzyme Inhib Med Chem. 2022 Dec;37(1):1227-1240. doi: 10.1080/14756366.2022.2062337. J Enzyme Inhib Med Chem. 2022. PMID: 35470754 Free PMC article.
-
Target Identification in Small Cell Lung Cancer via Integrated Phenotypic Screening and Activity-Based Protein Profiling.Mol Cancer Ther. 2016 Feb;15(2):334-42. doi: 10.1158/1535-7163.MCT-15-0444. Epub 2016 Jan 15. Mol Cancer Ther. 2016. PMID: 26772203 Free PMC article.
-
Discovery and Optimization of Narrow Spectrum Inhibitors of Tousled Like Kinase 2 (TLK2) Using Quantitative Structure Activity Relationships.bioRxiv [Preprint]. 2023 Dec 28:2023.12.28.573261. doi: 10.1101/2023.12.28.573261. bioRxiv. 2023. Update in: Eur J Med Chem. 2024 May 5;271:116357. doi: 10.1016/j.ejmech.2024.116357. PMID: 38234837 Free PMC article. Updated. Preprint.
-
Chemical interrogation of the malaria kinome.Chembiochem. 2014 Sep 5;15(13):1920-30. doi: 10.1002/cbic.201400025. Epub 2014 Aug 8. Chembiochem. 2014. PMID: 25111632 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Chemical Information
Miscellaneous